Array BioPharma

What Array BioPharma does

Array BioPharma is a Boulder, Colorado-based biopharmaceutical company founded in 1998 that develops and commercializes targeted small-molecule oncology drugs, with a domain specialization in BRAF and MEK kinase inhibitors. Following its acquisition by Pfizer, it operates as a wholly-owned subsidiary within one of the world's premier biopharmaceutical companies, with its oncology assets (BRAFTOVI/encorafenib and Mektovi/binimetinib) commercialized via Pfizer's global pharmaceutical distribution infrastructure.

The company's core products address BRAF-driven cancers. BRAFTOVI (encorafenib), a BRAF kinase inhibitor, was approved by the FDA in combination with cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC), supported by Pfizer's Phase 3 BREAKWATER trial demonstrating improved objective response rate, progression-free survival, and overall survival. In January 2026, the FDA approved Guardant Health's Guardant360 CDx as a companion diagnostic to identify eligible patients via non-invasive liquid biopsy. Mektovi (binimetinib), a MEK inhibitor, is co-administered with BRAFTOVI in combination regimens for BRAF-mutant solid tumors including melanoma. The company's customer base spans oncologists, oncology centers, hospitals, and specialty pharmacies.

Array BioPharma's revenue model is pharmaceutical drug sales of proprietary oncology therapeutics, with revenue now flowing entirely through Pfizer's consolidated commercial operations following the acquisition. Pricing is not publicly disclosed in the source material. The company employs 101-250 people, was previously listed on NASDAQ under ticker ARRY before being delisted upon acquisition, and has a prior leadership team including CEO Robert Conway and COO David L. Snitman.

Name

Array BioPharma

Legal name

Array BioPharma

Website

https://arraybiopharma.com

Company type

Private

Founded year

1998

Operating status

Acquired

Headcount range

101–250 employees

Short description

Array BioPharma is a Boulder-based biopharmaceutical company specializing in BRAF and MEK kinase inhibitors for oncology, now operating as a wholly-owned Pfizer subsidiary commercializing BRAFTOVI and Mektovi for BRAF-driven cancers including metastatic colorectal cancer.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Targeted oncology therapeutics
• Small molecule drugs
• BRAF kinase inhibitors
• MEK kinase inhibitors
• Biopharmaceutical drug development

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical drug sales: Revenue from commercialization of proprietary oncology drugs such as BRAFTOVI (encorafenib) and Mektovi (binimetinib). Following Pfizer's acquisition of Array BioPharma, drug sale revenue flows through Pfizer's pharmaceutical commercial operations.

Go-to-market motion1 record

Distribution channels2 records

Core offering

Array BioPharma is a biopharmaceutical company that develops and commercializes targeted small molecule oncology drugs, most notably BRAFTOVI (encorafenib), a BRAF kinase inhibitor, and Mektovi (binimetinib), a MEK inhibitor, used as combination regimens for BRAF V600E-mutant metastatic colorectal cancer and other BRAF-driven cancers. Following its acquisition by Pfizer, the company's assets are developed and commercialized within Pfizer's oncology franchise, including the Phase 3 BREAKWATER trial supporting BRAFTOVI's expanded indication.

Differentiator

Problem solved

Functional benefit

Brands

• BRAFTOVI: BRAFTOVI (encorafenib) is a BRAF inhibitor developed by Array BioPharma, indicated (in combination with cetuximab and chemotherapy) for BRAF V600E-mutant metastatic colorectal cancer and previously approved for melanoma.
• Mektovi

Products and services

• BRAFTOVI (encorafenib) BRAFTOVI (encorafenib) is a BRAF kinase inhibitor indicated in combination with cetuximab and chemotherapy for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC); previously approved for melanoma. It is a targeted oncology therapy commercialized within Pfizer's oncology franchise post-acquisition.
• Mektovi (binimetinib) Mektovi (binimetinib) is a MEK inhibitor co-developed by Array BioPharma and used in combination regimens alongside BRAFTOVI for the treatment of BRAF-mutant cancers, including melanoma.

Quantifiable outcome

• Improved objective response rate, progression-free survival, and overall survival with encorafenib-based combination in BRAF V600E-mutant mCRC (Phase 3 BREAKWATER trial)
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Guardant HealthcoreTechnology or Integration · 22 January 2026Guardant Health's Guardant360 CDx was FDA-approved as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for Array BioPharma's BRAFTOVI in combination with cetuximab and chemotherapy. This represents Guardant360 CDx's 25th companion diagnostic indication across multiple tumor types, enabling non-invasive liquid biopsy-based patient identification.
• PfizerflagshipStrategic or Co-development PartnerPfizer acquired Array BioPharma and now leads the commercialization and clinical development of Array BioPharma's oncology assets. Pfizer's Phase 3 BREAKWATER trial supported the FDA approval of BRAFTOVI in BRAF V600E-mutant mCRC. The integration places Array BioPharma's pipeline within one of the world's premier biopharmaceutical companies.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Roche: Roche markets vemurafenib (Zelboraf), the first FDA-approved BRAF inhibitor, and cobimetinib (Cotellic), a MEK inhibitor, forming a direct competitive combination therapy to Array BioPharma's BRAFTOVI/Mektovi in BRAF-mutant cancers.
• Novartis: Novartis markets dabrafenib (Tafinlar) and trametinib (Mekinist), a direct BRAF/MEK inhibitor combination that competes directly with Array BioPharma's BRAFTOVI/Mektovi regimen in BRAF-mutant melanoma and other BRAF-driven cancers.
• Genentech: Genentech (a Roche subsidiary) developed vemurafenib and cobimetinib, making it a direct competitor to Array BioPharma in the BRAF/MEK inhibitor space for BRAF-mutant cancers.

Broad incumbents

• Pfizer: Pfizer is Array BioPharma's parent company and a premier biopharmaceutical company with a broad oncology portfolio. Pfizer acquired Array BioPharma and now leads commercialization of Array's drugs, making it both the parent and a broad incumbent in the oncology space.
• Merck & Co. Merck is a premier biopharmaceutical company with a leading oncology franchise (Keytruda). Its scale, commercial reach, and oncology pipeline make it a broad incumbent in the oncology drug market.
• Amgen: Amgen is a large biopharmaceutical company with an oncology portfolio including targeted therapies. Its scale and commercial infrastructure make it a broad incumbent in oncology drug development and commercialization.
• AstraZeneca: AstraZeneca has a significant oncology portfolio including targeted therapies across multiple cancer types. Its scale and oncology pipeline breadth position it as a broad incumbent competitor in the targeted oncology space.
• Bristol-Myers Squibb: Bristol-Myers Squibb is a major oncology biopharmaceutical company with targeted therapy offerings including Opdivo and Yervoy. It competes broadly in the oncology space where Array BioPharma's BRAFTOVI operates.

Others

• Guardant Health: Guardant Health is Array BioPharma's companion diagnostic partner, with its Guardant360 CDx FDA-approved to identify BRAF V600E-mutant mCRC patients eligible for BRAFTOVI. As a precision oncology diagnostics company, it is an enabling partner in Array BioPharma's treatment ecosystem.

Emerging players

• BeiGene: BeiGene is an emerging oncology biopharmaceutical company developing targeted therapies including BTK inhibitors and immuno-oncology agents. It represents an emerging player in the oncology space with growing global commercialization capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/arraybiopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Array BioPharma